PD-L1-PD-1 pathway blockade improves overall survival (OS) in non-small-cell lung cancer (NSCLC), urothelial carcinoma, melanoma, and renal cell carcinoma patients [11–14]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.